Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models.
Neutralizing IL-17 protects the optic nerve from autoimmune pathology and prevents retinal nerve fiber layer atrophy during experimental autoimmune encephalomyelitis.
Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments.
Seroprevalence of NMO-IgG Antibody in Neuromyelitis optica (NMO) and Its Specificity in Differentiating NMO from Other Demyelinating Diseases with Overlap Symptoms: An Iranian Experience.
Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4.
Evaluating Neurocognitive Deficits in Patients with Multiple Sclerosis via a Brief Neuropsychological Approach.
Effect of comorbidity on mortality in multiple sclerosis.
Astrogliopathy and oligodendrogliopathy are early events in CNS demyelination.
Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort.
CCL2 induction by 1,25(OH)2D3 in dendritic cells from healthy donors and multiple sclerosis patients.
Axonal loss of retinal neurons in multiple sclerosis associated with optic radiation lesions.
Study of curcumin immunomodulatory effects on reactive astrocyte cell function.
Fitness and cognitive processing speed in persons with multiple sclerosis: A cross-sectional investigation.
Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.
The Potential of Metabolic Imaging.
Nanotechnology in neurology: Genesis, current status, and future prospects.
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
A simple test of choice stepping reaction time for assessing fall risk in people with multiple sclerosis.
The role of speed versus working memory in predicting learning new information in multiple sclerosis.
Enriched CD161high CCR6+ γδ T cells in the cerebrospinal fluid of patients with multiple sclerosis.
First-line urological evaluation in multiple sclerosis: validation of a specific decision-making algorithm.
Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis.
Myelin water mapping by spatially regularized longitudinal relaxographic imaging at high magnetic fields.
A population-based study of fall risk factors among people with multiple sclerosis in Stockholm county.
Increased thyroid autoimmunity among women with multiple sclerosis in the postpartum setting.
Pages
« first
‹ previous
…
430
431
432
433
434
435
436
437
438
…
next ›
last »